Halozyme Therapeutics Inc., of San Diego, said it has entered a $150 million credit agreement, secured by future royalties of Enhanze products, received only from the company's collaborations with Roche AG, of Basel, Switzerland, and Baxalta Inc., of Bannockburn, Ill. The financing will be facilitated through investment funds managed by Pharmakon Advisors and Athyrium Capital Management.